Brief: Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases
24/02/2026 22:51
Feb 24 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES HOTH THERAPEUTICS INC - 100% OF COHORT PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATA HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHING HOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION Source text: ID:nPn3Df7y0a Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology